Is BKL takeover target?, page-7

Full year results for BKL are not a mystery due to their quarterly reporting.

2017 full year Revenue is expected around $666m (2016 - $717m; 2015 - $472m)
2017 full year EBITDA is expected around $93m (2016 - $153m; 2015 - $79m)
2017 full year NPAT is expected around $57m (2016 - $100m; 2015 - $47m)

China in country sales and export sales are growing and expected around $120m for 2017 (2016 - $48m)

BKL is exploring partnerships in medicinal cannabis through BioCeuticals refer page 10 of 2016 annual report.

Lots of good news is not being noticed or being ignored. Year 2016 was an exceptional year. Drop in gross margins in 2017 due to drop in Australian revenues is being construed as a big negative albeit most of that revenue gap has been filled in by significant growth in other sources of revenues.

Expecting 2018 will be a bumper year and potential to beat 2016 revenues of $717m as revenues only need to grow 8% where as in some areas it is growing at more than 50%